Session (CTI)

ISSUE: The Maryland Prescription Drug Advisory Board (PDAB) was the first to be enacted under State legislature. Are there opportunities to improve the ways key stakeholders engage with PDABs, and provide evidence to support PDAB affordability reviews? We delve into the perspectives of a PDAB Executive Director, manufacturers and a patient group. The panelists agree that open and fair dialogue is essential for PDAB processes, using the experience of the Maryland PDAB thus far as an example to provide constructive advice for those engaging or about to engage in the process. The panel seeks to explore how patient groups and manufacturers can effectively engage with PDABs to allow a fair and transparent review of selected medicines. OVERVIEW: The moderator will provide an overview of PDABs and how they fit into the broader access landscape in the US. In increasingly challenging times of healthcare spending, States are seeking ways to curtail and manage their expenditure on prescription drugs. PDABs have emerged as a policy solution in multiple states. This panel seeks to explore how stakeholders, including patient groups and manufacturers, can effectively engage with PDABs to support a consistent, fair and transparent review of selected medicines.

• Andrew York will discuss how we can work to make an imperfect system better for all stakeholders and ensure that patients get access to the drugs they need.
• Kathryn Chandra will discuss challenges and opportunities in PDAB drug selection and affordability review processes.
• Tiffany Westrich-Robertson will discuss the issues around patient and patient group involvement in the PDAB processes.